Continue to site >
Trending ETFs

Name

As of 06/24/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$146.94

$968 M

0.00%

0.82%

Vitals

YTD Return

10.5%

1 yr return

26.2%

3 Yr Avg Return

-0.5%

5 Yr Avg Return

6.7%

Net Assets

$968 M

Holdings in Top 10

44.6%

52 WEEK LOW AND HIGH

$144.7
N/A
N/A

Expenses

OPERATING FEES

Expense Ratio 0.82%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover 47.30%

Redemption Fee N/A


Min Investment

Standard (Taxable)

$100,000

IRA

N/A


Fund Classification

Fund Type

Open End Mutual Fund


Name

As of 06/24/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$146.94

$968 M

0.00%

0.82%

FTDZX - Profile

Distributions

  • YTD Total Return 10.5%
  • 3 Yr Annualized Total Return -0.5%
  • 5 Yr Annualized Total Return 6.7%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.33%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annual

Fund Details

  • Legal Name
    FRANKLIN BIOTECHNOLOGY DISCOVERY FUND
  • Fund Family Name
    Franklin Templeton Group of Funds
  • Inception Date
    Oct 11, 2012
  • Shares Outstanding
    1024490
  • Share Class
    Adv
  • Currency
    USD
  • Domiciled Country
    US
  • Manager
    Evan McCulloch

Fund Description

Under normal market conditions, the Fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The Fund predominantly invests in equity securities. For the Fund’s investment purposes, a biotechnology company or discovery research firm is one that has at least 50% of its earnings derived from biotechnology activities, or at least 50% of its assets devoted to such activities, based on the company’s most recent fiscal year. Discovery research firms are in the early stages of drug research. Biotechnology activities are research, development, manufacture, and distribution of various biotechnological or biomedical products, services, and processes. This may include companies involved with genomics, genetic engineering, and gene therapy. It also includes companies involved in the application and development of biotechnology in areas such as health care, pharmaceuticals, and agriculture. In addition to its investments in biotechnology companies, the Fund may also invest up to 20% of its net assets in equity or debt securities of any type of issuer. The Fund is a "non-diversified" fund, which means it generally invests a greater portion of its assets in the securities of one or more issuers and invests overall in a smaller number of issuers than a diversified fund.

The Fund may invest a substantial portion of its assets in equity securities of smaller capitalization companies, which are generally companies with market capitalizations of less than $2 billion at the time of the Fund’s investment.

The Fund anticipates that, under normal conditions, it will invest more of its assets in U.S. securities than in securities of any other single country. It is currently anticipated that the Fund’s investments in foreign securities will not exceed 20% of its total assets. The Fund may buy foreign securities that are traded in the U.S. or in foreign markets, as well as American, European, and Global Depositary Receipts.

The investment manager is a research driven, fundamental investor, pursuing a growth strategy. As a "bottom-up" investor focusing primarily on individual securities, the investment manager seeks companies that have identifiable drivers of future earnings growth and that present, in the investment manager's opinion, the best trade-off between that potential earnings growth, business and financial risk, and valuation. Also, in seeking sustainable growth characteristics, the investment manager looks for companies that it believes can produce sustainable earnings growth and cash flow growth or the potential to generate income.

Read More

FTDZX - Performance

Return Ranking - Trailing

Period FTDZX Return Category Return Low Category Return High Rank in Category (%)
YTD 10.5% -25.7% 27.3% 33.95%
1 Yr 26.2% -25.7% 33.3% 1.85%
3 Yr -0.5%* -35.1% 13.7% 61.94%
5 Yr 6.7%* -5.9% 16.4% 75.36%
10 Yr 6.1%* -0.5% 13.1% 82.24%

* Annualized

Return Ranking - Calendar

Period FTDZX Return Category Return Low Category Return High Rank in Category (%)
2023 18.7% -12.6% 19.0% 2.47%
2022 -12.8% -53.9% 3.2% 50.32%
2021 -27.9% -39.6% 24.2% 96.77%
2020 14.4% -13.6% 178.2% 45.03%
2019 23.9% 3.8% 63.8% 30.37%

Total Return Ranking - Trailing

Period FTDZX Return Category Return Low Category Return High Rank in Category (%)
YTD 10.5% -25.7% 27.3% 33.95%
1 Yr 26.2% -25.7% 33.3% 1.85%
3 Yr -0.5%* -35.1% 13.7% 61.94%
5 Yr 6.7%* -5.9% 16.4% 75.36%
10 Yr 6.1%* -0.5% 13.1% 82.24%

* Annualized

Total Return Ranking - Calendar

Period FTDZX Return Category Return Low Category Return High Rank in Category (%)
2023 18.7% -12.6% 19.0% 2.47%
2022 -12.4% -53.9% 3.7% 64.52%
2021 -17.5% -33.9% 26.0% 94.84%
2020 30.2% -0.7% 180.6% 31.79%
2019 35.2% 4.6% 63.8% 10.37%

NAV & Total Return History


FTDZX - Holdings

Concentration Analysis

FTDZX Category Low Category High FTDZX % Rank
Net Assets 968 M 7.41 M 47.2 B 49.38%
Number of Holdings 93 25 420 38.27%
Net Assets in Top 10 400 M 2.19 M 22.7 B 53.70%
Weighting of Top 10 44.60% 17.8% 78.7% 58.02%

Top 10 Holdings

  1. Amgen, Inc. 8.52%
  2. Regeneron Pharmaceuticals, Inc. 6.81%
  3. Vertex Pharmaceuticals, Inc. 5.95%
  4. Ascendis Pharma A/S 3.78%
  5. Gilead Sciences, Inc. 3.61%
  6. Biogen, Inc. 3.56%
  7. Institutional Fiduciary Trust - Money Market Portfolio 3.47%
  8. Intra-Cellular Therapies, Inc. 3.25%
  9. AstraZeneca plc 2.95%
  10. Jazz Pharmaceuticals plc 2.70%

Asset Allocation

Weighting Return Low Return High FTDZX % Rank
Stocks
95.27% 89.34% 106.13% 83.95%
Cash
5.42% 0.00% 34.44% 20.37%
Preferred Stocks
0.37% 0.00% 7.86% 26.54%
Convertible Bonds
0.37% 0.00% 0.37% 2.55%
Other
0.00% -22.99% 23.31% 79.63%
Bonds
0.00% 0.00% 12.39% 72.84%

Stock Sector Breakdown

Weighting Return Low Return High FTDZX % Rank
Healthcare
99.75% 59.26% 100.00% 59.24%
Basic Materials
0.25% 0.00% 7.16% 28.66%
Utilities
0.00% 0.00% 0.00% 64.33%
Technology
0.00% 0.00% 22.69% 67.52%
Real Estate
0.00% 0.00% 5.89% 66.88%
Industrials
0.00% 0.00% 7.02% 67.52%
Financial Services
0.00% 0.00% 1.60% 72.61%
Energy
0.00% 0.00% 0.00% 64.33%
Communication Services
0.00% 0.00% 9.11% 64.97%
Consumer Defense
0.00% 0.00% 25.73% 68.79%
Consumer Cyclical
0.00% 0.00% 1.92% 66.88%

Stock Geographic Breakdown

Weighting Return Low Return High FTDZX % Rank
US
95.27% 69.36% 104.41% 49.38%
Non US
0.00% 0.00% 27.72% 85.80%

FTDZX - Expenses

Operational Fees

FTDZX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.82% 0.08% 4.28% 63.58%
Management Fee 0.61% 0.03% 1.25% 25.93%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee 0.15% 0.03% 0.25% 67.57%

Sales Fees

FTDZX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% 50.00%
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

FTDZX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 1.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

FTDZX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 47.30% 0.00% 238.00% 49.28%

FTDZX - Distributions

Dividend Yield Analysis

FTDZX Category Low Category High FTDZX % Rank
Dividend Yield 0.00% 0.00% 6.24% 77.78%

Dividend Distribution Analysis

FTDZX Category Low Category High Category Mod
Dividend Distribution Frequency Annual Annual Annual Annual

Net Income Ratio Analysis

FTDZX Category Low Category High FTDZX % Rank
Net Income Ratio -0.33% -2.54% 1.85% 58.71%

Capital Gain Distribution Analysis

FTDZX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Distributions History

View More +

FTDZX - Fund Manager Analysis

Managers

Evan McCulloch


Start Date

Tenure

Tenure Rank

Sep 15, 1997

24.72

24.7%

Mr. McCulloch, CFA, joined Franklin Templeton Investments in 1992.

Wendy Lam


Start Date

Tenure

Tenure Rank

Sep 01, 2018

3.75

3.8%

Ms. Lam has joined Franklin Templeton Investments in 2016. Prior to joining Franklin Templeton, Ms. Lam was an Executive Director and Senior Analyst covering large-cap biotechnology for Oppenheimer & Co and had been an Equity Research Associate at Bank of America Merrill Lynch, Morgan Stanley and Oppenheimer & Co. Ms. Lam has a Ph.D degree.

Akiva Felt


Start Date

Tenure

Tenure Rank

Jan 27, 2020

2.34

2.3%

Mr. Felt has been a portfolio manager, providing research and advice on the purchases and sales of individual securities and portfolio risk assessment. He joined Franklin Templeton in 2018. Prior to joining Franklin Templeton, Mr. Felt was a Senior Research Analyst with Asymmetry Capital, a healthcare focused hedge fund. He has covered the biotechnology sector since 2007 in increasing capacities on the sell-side, most recently as Managing Director for Oppenheimer & Co.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.02 24.72 7.87 0.25